REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy | AVESİS

Ege University Research Information System

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

Perol M., Ciuleanu T., Arrieta O., Prabhash K., Syrigos K. N. , Goeksel T. , ...More

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

Publication Type: Conference Paper / Summary Text
Volume: 32
City: Illinois
Country: United States Of America